Yuanyuan Fu1, Nicoletta Biglia2, Zhanwei Wang3, Yi Shen3, Harvey A Risch4, Lingeng Lu4, Emilie Marion Canuto5, Wei Jia3, Dionyssios Katsaros5, Herbert Yu6. 1. Cancer Epidemiology Program, University of Hawaii Cancer Center, United States; Department of Molecular Biosciences and Bioengineering, University of Hawaii at Manoa, United States. 2. Department of Surgical Sciences, University of Turin, Torino, Italy. 3. Cancer Epidemiology Program, University of Hawaii Cancer Center, United States. 4. Department of Chronic Disease Epidemiology, Yale School of Public Health, United States. 5. Department of Surgical Sciences, Azienda Ospedaliero-Universitaria, Turin, Italy. 6. Cancer Epidemiology Program, University of Hawaii Cancer Center, United States. Electronic address: hyu@cc.hawaii.edu.
Abstract
OBJECTIVE: Long non-coding RNAs (lncRNAs) are a class of non-protein coding transcripts that has gained significant attention lately due to their important biological actions and potential involvement in cancer. Ovarian cancer is a devastating disease with poor prognosis, and our understanding of lncRNA's involvement in the malignancy is limited. To further our knowledge, we measured the expression of three lncRNAs, ASAP1-IT1, FAM215A, and LINC00472, in tumor samples, and analyzed their associations with disease characteristics and patient survival. METHODS: Two hundred sixty-six patients diagnosed with primary epithelial ovarian cancers were recruited for the study. Fresh-frozen tumor samples were obtained from the patients at tumor resection and analyzed by RT-qPCR for expression of ASAP1-IT1, FAM215A, and LINC00472. Associations of lncRNA expression with patient survival were determined using Cox proportional hazards regression models. RESULTS: We observed high expression of ASAP1-IT1, FAM215A and LINC00472 more frequently in low grade tumors and early stage disease compared to high grade tumors and late stage disease, respectively. High expression of ASAP1-IT1 and FAM215A were associated with favorable overall survival, and the survival association with ASAP1-IT1 was independent of tumor grade and disease stage. Analyses of online data also demonstrated similar survival associations with ASAP1-IT1 and FAM215A, suggesting that these lncRNAs may be involved in ovarian cancer progression. CONCLUSIONS: LncRNAs may play appreciable roles in ovarian cancer and more research is needed to elucidate their biological mechanisms and clinical implications in tumor characterization as well as disease prognosis and treatment.
OBJECTIVE: Long non-coding RNAs (lncRNAs) are a class of non-protein coding transcripts that has gained significant attention lately due to their important biological actions and potential involvement in cancer. Ovarian cancer is a devastating disease with poor prognosis, and our understanding of lncRNA's involvement in the malignancy is limited. To further our knowledge, we measured the expression of three lncRNAs, ASAP1-IT1, FAM215A, and LINC00472, in tumor samples, and analyzed their associations with disease characteristics and patient survival. METHODS: Two hundred sixty-six patients diagnosed with primary epithelial ovarian cancers were recruited for the study. Fresh-frozen tumor samples were obtained from the patients at tumor resection and analyzed by RT-qPCR for expression of ASAP1-IT1, FAM215A, and LINC00472. Associations of lncRNA expression with patient survival were determined using Cox proportional hazards regression models. RESULTS: We observed high expression of ASAP1-IT1, FAM215A and LINC00472 more frequently in low grade tumors and early stage disease compared to high grade tumors and late stage disease, respectively. High expression of ASAP1-IT1 and FAM215A were associated with favorable overall survival, and the survival association with ASAP1-IT1 was independent of tumor grade and disease stage. Analyses of online data also demonstrated similar survival associations with ASAP1-IT1 and FAM215A, suggesting that these lncRNAs may be involved in ovarian cancer progression. CONCLUSIONS: LncRNAs may play appreciable roles in ovarian cancer and more research is needed to elucidate their biological mechanisms and clinical implications in tumor characterization as well as disease prognosis and treatment.
Authors: Jonathan L Blank; Xiaozhen J Liu; Katherine Cosmopoulos; David C Bouck; Khristofer Garcia; Hugues Bernard; Olga Tayber; Greg Hather; Ray Liu; Usha Narayanan; Michael A Milhollen; Eric S Lightcap Journal: Cancer Res Date: 2012-10-24 Impact factor: 12.701
Authors: Divya Khaitan; Marcel E Dinger; Joseph Mazar; Joanna Crawford; Martin A Smith; John S Mattick; Ranjan J Perera Journal: Cancer Res Date: 2011-05-10 Impact factor: 12.701
Authors: Dong Lin; Akira Watahiki; Jane Bayani; Fang Zhang; Lin Liu; Victor Ling; Marianne D Sadar; John English; Ladan Fazli; Alan So; Peter W Gout; Martin Gleave; Jeremy A Squire; Yu-Zhuo Wang Journal: Cancer Res Date: 2008-06-01 Impact factor: 12.701
Authors: Yi Shen; Zhanwei Wang; Lenora W M Loo; Yan Ni; Wei Jia; Peiwen Fei; Harvey A Risch; Dionyssios Katsaros; Herbert Yu Journal: Breast Cancer Res Treat Date: 2015-11-13 Impact factor: 4.872
Authors: Helder I Nakaya; Paulo P Amaral; Rodrigo Louro; André Lopes; Angela A Fachel; Yuri B Moreira; Tarik A El-Jundi; Aline M da Silva; Eduardo M Reis; Sergio Verjovski-Almeida Journal: Genome Biol Date: 2007 Impact factor: 13.583
Authors: Jennifer B Permuth; Dung-Tsa Chen; Sean J Yoder; Jiannong Li; Andrew T Smith; Jung W Choi; Jongphil Kim; Yoganand Balagurunathan; Kun Jiang; Domenico Coppola; Barbara A Centeno; Jason Klapman; Pam Hodul; Florian A Karreth; Jose G Trevino; Nipun Merchant; Anthony Magliocco; Mokenge P Malafa; Robert Gillies Journal: Sci Rep Date: 2017-09-05 Impact factor: 4.379
Authors: Brigitta László; László Antal; Eszter Gyöngyösi; Anita Szalmás; Szilárd Póliska; György Veress; József Kónya Journal: BMC Cancer Date: 2021-06-07 Impact factor: 4.430